{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-022271","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.609000+00:00","generated_at":"2026-06-24T01:22:28.731483+00:00","sec_items":["3.02","5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aquestive appoints new CMO and adds independent director to Board","bullets":["Appointed Kenneth Truitt, M.D. as Chief Medical Officer effective Sept 6, 2022.","Dr. Truitt granted inducement option for 100,000 shares; vesting 25%/25%/50% over 3 years.","Appointed Timothy E. Morris to Board (Class I) effective Aug 5, 2022, filling newly created seat.","Mr. Morris receives 28,500 stock options vesting 1/3 annually; will serve on Audit Committee.","Board Chair Santo Costa steps down from Audit Committee; Board size increased to seven."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-022271","json":"https://secwatch.observer/filing/0001628280-22-022271.json","markdown":"https://secwatch.observer/filing/0001628280-22-022271.md","text":"https://secwatch.observer/filing/0001628280-22-022271.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000162828022022271/0001628280-22-022271-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000162828022022271/aqst-20220810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:22:28.731483+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2b651503e7","claim":"Timothy E. Morris was appointed as Director at Aquestive Therapeutics, Inc..","evidence_excerpt":"On August 10, 2022, the Company announced the appointment of Timothy E. Morris to the Company’s Board, effective August 5, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1398733/000162828022022271/0001628280-22-022271-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}